Institution
Lahore General Hospital
Healthcare•Lahore, Pakistan•
About: Lahore General Hospital is a healthcare organization based out in Lahore, Pakistan. It is known for research contribution in the topics: Medicine & Population. The organization has 422 authors who have published 311 publications receiving 1929 citations.
Papers published on a yearly basis
Papers
More filters
••
Yonsei University1, University of Indonesia2, Aga Khan University3, University of Tartu4, Alfaisal University5, Ziauddin University6, Dubai Health Authority7, Shaikh Zayed Hospital8, Baqiyatallah University of Medical Sciences9, King Saud University10, King Saud bin Abdulaziz University for Health Sciences11, American University of Beirut12, Sungkyunkwan University13, University of Balamand14, Khyber Medical University15, University of Peshawar16, Reykjavík University17, RMIT University18, University of Ljubljana19, La Trobe University20, University of New South Wales21, University of Pécs22, University Medical Center Rizk Hospital23, University of Iceland24, Soonchunhyang University25, Cleveland Clinic26, Vilnius University27, Vilnius Gediminas Technical University28, University of Ulsan29, Tehran University of Medical Sciences30, Aims Community College31, University of Sydney32, Eijkman Institute for Molecular Biology33, Memorial Hospital of South Bend34, Pakistan Institute of Development Economics35, Military Hospital36, Saint Joseph's University37, Allama Iqbal Medical College38, Hiroshima University39, Lahore General Hospital40, Holy Family Hospital41, Rawalpindi Medical College42, Dow Medical College43
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Abstract: The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
463 citations
••
TL;DR: Eltrombopag reduced the need for platelet transfusions in patients with chronic liver disease who were undergoing elective invasive procedures, but it was associated with an increased incidence of portal-vein thrombosis, as compared with placebo.
Abstract: Background Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure. Methods We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7 days after the procedure. A key secondary end point was the occurrence of bleeding (World Health Organization [WHO] grade 2 or higher) during this period. Results A platelet transfusion was avoided in 104 of 145 patients who received eltrombopag (72%) and in 28 of 147 who received placebo (19%) (P<0...
265 citations
••
University of Pennsylvania1, University of Helsinki2, University of Cambridge3, Stanford University4, Lund University5, McMaster University6, University of Tokyo7, Imperial College London8, National University of Singapore9, University of Oklahoma Health Sciences Center10, Icahn School of Medicine at Mount Sinai11, Punjab Institute of Cardiology12, Karachi Institute of Heart Diseases13, Civil Hospital Karachi14, Liaquat National Hospital15, King Edward Medical University16, Lahore General Hospital17, All India Institute of Medical Sciences18, Los Angeles Biomedical Research Institute19, National Health Research Institutes20, National Taiwan University21, National Defense Medical Center22, International Centre for Diarrhoeal Disease Research, Bangladesh23, MedStar Washington Hospital Center24, Frederiksberg Hospital25, Copenhagen University Hospital26, Leiden University Medical Center27, University of Glasgow28, Columbia University29, National Institutes of Health30
TL;DR: A genome-wide, multi-ancestry study of genetic variation for type 2 diabetes and coronary heart disease finds variants associated with both outcomes implicate new pathways as well as targets of existing drugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.
Abstract: Danish Saleheen, Benjamin Voight and colleagues perform genome-wide analysis of multi-ancestry cohorts to identify genetic associations with type 2 diabetes (T2D) and coronary heart disease (CHD). They find novel loci and show that 24% of T2D loci are also associated with CHD and that greater genetic risk of T2D increases risk of CHD. To evaluate the shared genetic etiology of type 2 diabetes (T2D) and coronary heart disease (CHD), we conducted a genome-wide, multi-ancestry study of genetic variation for both diseases in up to 265,678 subjects for T2D and 260,365 subjects for CHD. We identify 16 previously unreported loci for T2D and 1 locus for CHD, including a new T2D association at a missense variant in HLA-DRB5 (odds ratio (OR) = 1.29). We show that genetically mediated increase in T2D risk also confers higher CHD risk. Joint T2D–CHD analysis identified eight variants—two of which are coding—where T2D and CHD associations appear to colocalize, including a new joint T2D–CHD association at the CCDC92 locus that also replicated for T2D. The variants associated with both outcomes implicate new pathways as well as targets of existing drugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.
193 citations
••
Ido Didi Fabian1, Ido Didi Fabian2, Elhassan Abdallah3, Shehu U. Abdullahi4 +473 more•Institutions (155)
TL;DR: This cross-sectional analysis reports the retinoblastoma stage at diagnosis across the world during a single year, investigates associations between clinical variables and national income level, and investigates risk factors for advanced disease at diagnosis.
Abstract: Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.
151 citations
••
University of Pennsylvania1, University of Cambridge2, Ludwig Maximilian University of Munich3, Erasmus University Rotterdam4, Children's Hospital of Philadelphia5, Punjab Institute of Cardiology6, Karachi Institute of Heart Diseases7, Liaquat National Hospital8, Dow University of Health Sciences9, Lahore General Hospital10, Harvard University11, Medical University of Graz12, University of Leicester13, University of Oxford14, Imperial College London15, University of Maryland, Baltimore16, Boston University17, University of Karachi18, Johns Hopkins University19, Emory University20, Aga Khan University21
TL;DR: Evidence from this study does not support a causal role of circulating serum urate levels in T2DM, CHD, ischemic stroke, or HF, and decreasing serum Urate levels may not translate into risk reductions for cardiometabolic conditions.
136 citations
Authors
Showing all 424 results
Name | H-index | Papers | Citations |
---|---|---|---|
Muhammad Zeeshan Shakir | 22 | 177 | 2782 |
Saima Ahmad | 10 | 46 | 352 |
Abhishek Thakur | 8 | 26 | 348 |
Azeem Khan | 7 | 20 | 218 |
Awais Amjad Malik | 6 | 37 | 153 |
Ajmal Farooq | 6 | 19 | 80 |
M. F. Nasir | 5 | 11 | 78 |
Ghias Un Nabi Tayyab | 5 | 14 | 400 |
Saima Ahmed | 5 | 11 | 70 |
Saulat Ullah Khan | 5 | 12 | 54 |
Saeed Mahmood | 4 | 9 | 74 |
Muhammad Junaid Tahir | 4 | 28 | 56 |
Mumtaz Ahmad | 4 | 6 | 96 |
Muna Malik | 4 | 7 | 35 |
Sadaf Khalid | 4 | 5 | 51 |